CYCLOSET® (BROMOCRIPTINE)
















  • Baseline A1C ∼8.9%
  • Difference between groups (0.4%) was statistically significant
  • Reference [1]
Cycloset® Monotherapy for 24 weeks in T2DM
Cycloset® 1.6 - 4.8 mg/day
(N=80)
Placebo
(N=79)
HgA1C
(average change from baseline)
-0.10% +0.3%

  • Baseline A1C ∼8.3%
  • Difference between groups (0.5%) was statistically significant
  • Reference [1]
Cycloset® added to metformin and sulfonylurea for 24 weeks in T2DM
Cycloset® 1.6 - 4.8 mg/day
(N=177)
Placebo
(N=90)
HgA1C
(average change from baseline)
-0.50% 0.0%







Reference [1]
Side effects of Cycloset in placebo-controlled trials
Side effect Cycloset 1.6 - 4.8 mg daily
(N=80)
Placebo
(N=79)
Nausea 33% 8%
Runny nose (Rhinitis) 14% 4%
Weakness 13% 6%
Headache 13% 9%
Dizziness 13% 8%
Constipation 11% 4%
Sinusitis 10% 3%
Diarrhea 9% 5%
Upset stomach 8% 3%
Vision changes 8% 1%
Vomiting 6% 1%
Decreased appetite 5% 1%